Clinical Scorecard: A Sequential Approach Utilizing Initial Radiofrequency Ablation Followed by Endoscopic Papillectomy for Challenging Ampullary Tumors
At a Glance
Category
Detail
Condition
Ampullary tumors
Key Mechanisms
Endoscopic papillectomy (EP) as first-line treatment; radiofrequency ablation (RFA) as adjunctive treatment.
Target Population
Patients with complex ampullary tumors.
Care Setting
Endoscopic treatment in a hospital setting.
Key Highlights
Technical success rate of 100% for EP and RFA.
Overall short-term clinical success rate of 96.6%.
Adverse events occurred in 20.5% of patients.
Tumor size is a significant risk factor for adverse events.
RFA group had a short-term clinical success rate of 91.7%.
Guideline-Based Recommendations
Diagnosis
Diagnosis of ampullary tumors should include endoscopic evaluation and histological assessment.
Management
Endoscopic papillectomy (EP) is the first-line treatment for ampullary tumors.
Radiofrequency ablation (RFA) may be used as an adjunctive treatment for larger or complex tumors.
Monitoring & Follow-up
Follow-up endoscopies are necessary to monitor for remnant or recurrent lesions.
Risks
Adverse events such as postprocedural pancreatitis and bleeding are associated with both EP and RFA.
Patient & Prescribing Data
Patients diagnosed with ampullary tumors treated at Shenzhen People’s Hospital.
Sequential RFA followed by EP may reduce adverse events in select patients.
Clinical Best Practices
Consider RFA for large ampullary tumors prior to EP to minimize bleeding risk.
Monitor for complications post-procedure, especially in patients with larger tumors.
